Ciba-Geigy Corporation

Armin Zust

Wolfgang Frostl

Angelo Storni

Roland Heckendorn

Georg Von Sprecher

Erich Schmid

Cesare Mondadori

Gunther Dorhofer

Dietrich Strub

Jacques Gosteli

Novel hydrogenated heterocyclic compounds, containing two nitrogen atoms, of the formula ##STR1## in which R.sub.1, R.sub.2, R.sub.3, R.sub.5 and Rhd 7 are each, independently of the others, hydrogen or lower alkyl, m is 2 or 3, n is 1 or 2, and either R.sub.4 and R.sub.6 are each hydrogen or R.sub.4 and R.sub.6 together form an additional bond, in free form or in form of a salt, can be used as pharmaceutical active ingredients and can be manufactured in a manner known per se.

Saturated tetracyclic nitrogen heterocycles

Novel hydrogenated heterocyclic compounds, containing two nitrogen atoms, of the formula ##STR1## in which R.sub.1, R.sub.2, R.sub.3, R.sub.5 and R.sub.7 are each, independently of the others, hydrogen or lower alkyl, m is 2 or 3, n is 1 or 2, and either R.sub.4 and R.sub.6 are each hydrogen or R.sub.4 and R.sub.6 together form an additional bond, in free form or in form of a salt, can be used as pharmaceutical active ingredients for memory improvement and can be manufactured in a manner known per se.

Hydrogenated nitrogen containing tetracycles having two nonadjacent

The invention relates to novel hydrogenated 1-benzooxacycloalkylpyridinecarboxylic acid compounds of formula ##STR1## in which the variables R.sub.1, R.sub.2, R.sub.3, R.sub.4, R.sub.5, alk, X, Z, m, n and p, the dotted line and the substituents of the ring A have the meanings indicated in the specification and in the claims, and to their tautomers and/or salts. These compounds can be used as pharmaceutical active ingredients and can be prepared in a manner known per se.

Hydrogenated 1-benzooxacycloalkylpyridinecarboxylic acid compounds and

The invention relates to novel hydrogenated 1-benzooxacycloalkylpyridinecarboxylic acid compounds of formula ##STR1## in which the variable R.sub.1, R.sub.2, R.sub.3, R.sub.4, R.sub.5, alk, X, Z, m, n and p, the dotted line and the substituents of the ring A have the meanings indicated in the specification and in the claims, and to their tautomers and/or salts. These compounds can be used as pharmaceutical active ingredients and can be prepared in a manner known per se.

Hydrogenated 1-benzooxacycloalkylpyridinecarboxylic acid compounds

Hydropyridine derivatives of the formula ##STR1## in which R.sub.1 represents carboxy, lower alkoxycarbonyl, carbamoyl, N-lower alkylcarbamoyl or N,N-di-lower alkylcarbamoyl, R.sub.2 represents hydrogen, an optionally etherified or acylated hydroxy group or an optionally acylated amino group, and R.sub.3 represents a radical of the formula R- (Ia), R-alk.sub.1 - (Ib) or R'=alk.sub.2 - (Ic) in which R represents a benzocycloalkenyl radical having a total of from 8 to 12 ring carbon atoms which is bonded via a saturated carbon atom and which is unsubstituted or is mono- or poly-substituted in the benzo moiety by hydroxy, lower alkoxy, lower alkanoyloxy, halogen, lower alkyl and/or by trifluoromethyl, and/or substituted in the .alpha.-position by lower alkyl, and R' represents a benzocycloalkylidene radical having a total of from 8 to 12 ring carbon atoms which is unsubstituted or is mono- or poly-substituted in the benzo moiety by hydroxy, lower alkoxy, lower alkanoyloxy, halogen, lower alkyl and/or by trifluoromethyl, and alk.sub.1 represents lower alkylene or lower alkylidene and alk.sub.2 represents lower alkyl-.omega.-ylidene, wherein the dotted line is intended to show that there may be a single bond or especially a double bond, and 3-aminopropionic acid compounds of the formula R.sub.3 --NH--CH.sub.2 CH.sub.2 --R.sub.1 (IVc) in which R.sub.1 and R.sub.3 have the meanings given above, and their pharmaceutically acceptable salts, have nootropic properties and can be used as nootropic active ingredients in medicaments. They are manufactured by methods known per se.

Hydropyridine derivatives

Hydropyridine derivatives of the formula ##STR1## in which R.sub.1 represents carboxy, lower alkoxycarbonyl, carbamoyl, N-lower alkylcarbamoyl or N,N-di-lower alkylcarbamoyl, R.sub.2 represents hydrogen, an optionally etherified or acylated hydroxy group or an optionally acylated amino group, and R.sub.3 represents a radical of the formula R-- (Ia), R--alk.sub.1 -- (Ib) or R'.dbd.alk.sub.2 -- (Ic) in which R represents a benzocycloalkenyl radical having a total of from 8 to 12 ring carbon atoms which is bonded via a saturated carbon atom and which is unsubstituted or is mono- or poly-substituted in the benzo moiety by hydroxy, lower alkoxy, lower alkanoyloxy, halogen, lower alkyl and/or by trifluoromethyl, and/or subsituted in the .alpha.-position by lower alkyl, and R' represents a benzocycloalkylidene radical having a total of from 8 to 12 ring carbon atoms which is unsubstituted or is mono- or poly-substituted in the benzo moiety by hydroxy, lower alkoxy, lower alkanoyloxy, halogen, lower alkyl and/or by trifluoromethyl, and alk.sub.1 represents lower alkylene or lower alkylidene and alk.sub.2 represents lower alkyl-.omega.-ylidene, wherein the dotted line is intended to show that there may be a single bond or especially a double bond, and 3-aminopropionic acid compounds of the formula R.sub.3 --NH--CH.sub.2 CH.sub.2 --R.sub.1 (IVc) in which R.sub.1 and R.sub.3 have the meanings given above, and their pharmaceutically acceptable salts, have nootropic properties and can be used as nootropic active ingredients in medicaments. They are manufactured by methods known per se.

The present invention provides new basically substituted pyridinecarboxamides having the formula I ##STR1## wherein R.sub.1 represents lower alkyl and --OR.sub.1 is in the adjacent position to the carboxamide group,

Antiemetic, psychosomatic and antipsychotic heterocyclic pyridine

The invention relates to new heterocyclic S-imino-S-oxides of the formula I ##STR1## in which one of the symbols X.sub.1 and X.sub.2 denotes a direct bond and the other denotes the vinylene group --CH=CH-- or the epithio radical --S--, Y.sub.1 and Y.sub.2 conjointly denote an additional bond or one of the symbols denotes hydrogen and the other denotes hydrogen or, conjointly with the symbol R.sub.1 or R.sub.2, which is present on the same carbon atom, denotes the oxo radical, one of the symbols R.sub.1 and R.sub.2 denotes hydrogen or lower alkyl and the other denotes hydrogen or lower alkyl or, conjointly with the symbol Y.sub.1 or Y.sub.2, which is present on the same carbon atom, denotes the oxo radical, or, if Y.sub.1 and Y.sub.2 conjointly denote an additional bond, also denotes lower alkoxy, and R.sub.3 and R.sub.4 independently of one another denote hydrogen, halogen up to atomic number 35, lower alkyl, lower alkoxy or trifluoromethyl and R.sub.5 denotes hydrogen or lower alkyl, and to their acid addition salts in particular the pharmaceutically with inorganic and organic acceptable acid addition salts. These new compounds possess valuable pharmacological properties. In particular they have an anticonvulsive activity and are useful for the treatment of epilepsy and of states of tension and states of agitation.

Heterocyclic S-imino-S-oxides

The invention relates to new aminoacyl compounds of the formula I, ##SPC1##

Growing community of inventors

Basel, Switzerland

Armin Zust